Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine

Inclusion Criteria: 1. Male or female aged over 40 years; 2. Diagnosis of primary inflammatory Knee Osteoarthritis (KOA), 3. Body mass index (BMI) of 18-32 kg/m2 at screening; 4. Patients with normal organ function at baseline 5. Contraceptives measures 6. In the investigator's opinion, the patient is capable and willing to comply with the requirements of the study; 7. Willing and able to sign a written informed consent; 8. Affiliated to social security insurance. Exclusion Criteria: 1. Systemic Autoimmune or immunodeficiency disease; 2. Administration of non-steroidal anti-inflammatory drug (NSAID): 3. Administration of prednisone or having intra-articular corticosteroid injection or bolus intramuscular or intravenous treatment with corticosteroids; 4. Patients treated with biologics such as anti-TNFAlpha, anti-IL-6 and anti-CD-20 5. Participation in another investigational drug or vaccine trial; 6. Knee surgery planned before screening and throughout the study; 7. Knee surgery within the year of baseline; 8. Knee trauma within 2 months of baseline; 9. Chronic hepatitis B and/or C infection. Patients with previous infection, resolved in the past, are eligible; 10. HIV-positivity; 11. History of allergic reaction to any constituents of the study drug; 12. Diagnosis or history of any inflammatory arthritis; 13. Neurologic disorders involving the lower limbs; 14. History of malignancy within the last 5 years; 15. Uncontrolled congestive heart failure or hypertension, unstable heart disease 16. Evidence of any clinically significant abnormality on a chest X-ray which, in the opinion of the investigator, could represent active infection or latent tuberculosis; 17. Moderate or severe acute illness/infection, persistent diarrhea or vomiting on the day of vaccination; 18. Received any licensed, non-live vaccine within the 14 days before receipt of any dose of the study vaccine or is scheduled to receive any licensed, non-live vaccine within 30 days following receipt of any dose of the study vaccine; 19. Receipt of immune globulins, blood or blood-derived products; 20. Pregnant or lactating females; 21. The investigator considers the patient unfit for the study as a result of the medical interview, physical examination, or screening investigations.